医学
鼻息肉
美波利祖马布
可视模拟标度
安慰剂
慢性鼻-鼻窦炎
内科学
嗅觉
析因分析
胃肠病学
外科
嗜酸性粒细胞
病理
哮喘
替代医学
神经科学
生物
作者
J Mullol,Valerie J. Lund,Martin Wagenmann,Joseph Han,Ana Sousa,Steven G. Smith,Bhabita Mayer,R H Chan,Wytske Fokkens
出处
期刊:Rhinology
[Rhinology]
日期:2024-01-01
摘要
BACKGROUND: Loss of smell is one of the most bothersome and difficult-to-treat symptoms in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP). METHODOLOGY: SYNAPSE was a 52-week Phase III study of 4-weekly mepolizumab (100 mg subcutaneously) plus standard of care in adults with severe bilateral CRSwNP. This post hoc analysis assessed changes from baseline to study end in loss of smell visual analogue scale (VAS) symptom score, in patients stratified by several baseline clinical characteristics. SinoNasal Outcomes Test (SNOT)-22 sense of smell/taste item and University of Pennsylvania Smell Identification Test (UPSIT) scores were also assessed. RESULTS: SYNAPSE enrolled 407 patients (mepolizumab=206; placebo=201) with impaired sense of smell at baseline. Improvements from baseline to study end in loss of smell VAS score were greater with mepolizumab versus placebo (treatment difference: −0.37) and most notable in patients with fewer or more recent prior surgeries (treatment difference: 1 vs 2 vs >2 prior surgeries,−1.29 vs −0.23 vs −0.07;
科研通智能强力驱动
Strongly Powered by AbleSci AI